Relevant bibliographies by topics / Breast – Cancer

Academic literature on the topic 'Breast – Cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast – Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast – Cancer"

1

DenizAtasoy, DenizAtasoy, FatihAydogan FatihAydogan, SevgiErgin SevgiErgin, KenanMidilli KenanMidilli, SennurIlvan SennurIlvan, CihanUras CihanUras, and AliCengiz AliCengiz. "Male Breast Cancer: No Evidence of Human Papillomavirus Etiology." International Journal of Surgery and Medicine 4, no. 3 (2019): 1. http://dx.doi.org/10.5455/ijsm.male-breast-cancer.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

V. Jagtap, Sunil, Suresh J. Bhosale, Gayatri N. Patel, and Swati S. Jagtap. "Bilateral Metachronous Breast Cancer." Indian Journal of Pathology: Research and Practice 8, no. 1 (2019): 122–25. http://dx.doi.org/10.21088/ijprp.2278.148x.8119.20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dias, Amanda de Araújo, Magda Nery Mauro, Taynah Cascaes Puy, Ciane Martins de Oliveira, Amanda Alves Fecury, Cláudio Alberto Gellis de Mattos Dias, Carla Viana Dendasck, and Euzébio de Oliveira. "Update on the Main Aspects Related to Breast Cancer." Revista Científica Multidisciplinar Núcleo do Conhecimento 04, no. 08 (November 21, 2017): 05–17. http://dx.doi.org/10.32749/nucleodoconhecimento.com.br/health/breast-cancer.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Holm, Johanna, Keith Humphreys, Jingmei Li, Alexander Ploner, Abbas Cheddad, Mikael Eriksson, Sven Törnberg, Per Hall, and Kamila Czene. "Risk Factors and Tumor Characteristics of Interval Cancers by Mammographic Density." Journal of Clinical Oncology 33, no. 9 (March 20, 2015): 1030–37. http://dx.doi.org/10.1200/jco.2014.58.9986.

Full text
Abstract:
Purpose To compare tumor characteristics and risk factors of interval breast cancers and screen-detected breast cancers, taking mammographic density into account. Patients and Methods Women diagnosed with invasive breast cancer from 2001 to 2008 in Stockholm, Sweden, with data on tumor characteristics (n = 4,091), risk factors, and mammographic density (n = 1,957) were included. Logistic regression was used to compare interval breast cancers with screen-detected breast cancers, overall and by highest and lowest quartiles of percent mammographic density. Results Compared with screen-detected breast cancers, interval breast cancers in nondense breasts (≤ 20% mammographic density) were significantly more likely to exhibit lymph node involvement (odds ratio [OR], 3.55; 95% CI, 1.74 to 7.13) and to be estrogen receptor negative (OR, 4.05; 95% CI, 2.24 to 7.25), human epidermal growth factor receptor 2 positive (OR, 5.17; 95% CI, 1.64 to 17.01), progesterone receptor negative (OR, 2.63; 95% CI, 1.58 to 4.38), and triple negative (OR, 5.33; 95% CI, 1.21 to 22.46). In contrast, interval breast cancers in dense breasts (> 40.9% mammographic density) were less aggressive than interval breast cancers in nondense breasts (overall difference, P = .008) and were phenotypically more similar to screen-detected breast cancers. Risk factors differentially associated with interval breast cancer relative to screen-detected breast cancer after adjusting for age and mammographic density were family history of breast cancer (OR, 1.32; 95% CI, 1.02 to 1.70), current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38 to 2.44), and body mass index more than 25 kg/m2 (OR, 0.49; 95% CI, 0.29 to 0.82). Conclusion Interval breast cancers in women with low mammographic density have the most aggressive phenotype. The effect of HRT on interval breast cancer risk is not fully explained by mammographic density. Family history is associated with interval breast cancers, possibly indicating disparate genetic background of screen-detected breast cancers and interval breast cancers.
APA, Harvard, Vancouver, ISO, and other styles
5

Gordon, Paula B. "The Impact of Dense Breasts on the Stage of Breast Cancer at Diagnosis: A Review and Options for Supplemental Screening." Current Oncology 29, no. 5 (May 17, 2022): 3595–636. http://dx.doi.org/10.3390/curroncol29050291.

Full text
Abstract:
The purpose of breast cancer screening is to find cancers early to reduce mortality and to allow successful treatment with less aggressive therapy. Mammography is the gold standard for breast cancer screening. Its efficacy in reducing mortality from breast cancer was proven in randomized controlled trials (RCTs) conducted from the early 1960s to the mid 1990s. Panels that recommend breast cancer screening guidelines have traditionally relied on the old RCTs, which did not include considerations of breast density, race/ethnicity, current hormone therapy, and other risk factors. Women do not all benefit equally from mammography. Mortality reduction is significantly lower in women with dense breasts because normal dense tissue can mask cancers on mammograms. Moreover, women with dense breasts are known to be at increased risk. To provide equity, breast cancer screening guidelines should be created with the goal of maximizing mortality reduction and allowing less aggressive therapy, which may include decreasing the interval between screening mammograms and recommending consideration of supplemental screening for women with dense breasts. This review will address the issue of dense breasts and the impact on the stage of breast cancer at the time of diagnosis, and discuss options for supplemental screening.
APA, Harvard, Vancouver, ISO, and other styles
6

Calinescu, Gina, Corina Grigoriu, Athir Eddan, Nicolae Bacalbasa, Irina Balescu, Bianca-Margareta Mihai, Roxana Elena Bohiltea, and Claudia Stoica. "Breast density and breast cancer." Romanian Journal of Medical Practice 16, S7 (December 30, 2021): 29–32. http://dx.doi.org/10.37897/rjmp.2021.s7.9.

Full text
Abstract:
Breast density is increasingly recognized as an independent risk factor for the development of breast cancer. It has been shown to be associated with a four-to sixfold increase a woman's risk of malignant breast disease. Increased breast density, as identified on mammography, is known to decrease the diagnostic sensitivity of the examination, which is of great concern to women at increased risk for breast cancer. Dense tissue has generally been associated with younger age and premenopausal status, with the assumption that breast density gradually decreases after menopause. However, the actual proportion of older women with dense breasts is unknown. Unfortunately, mammography is less accurate on dense breast tissue compared to fattier breast tissue. Multiple studies suggest a solution to this by demonstrating the ability of supplemental screening ultrasound to detect additional malignant lesions in women with dense breast tissue but with negative mammography. Improved screening methods for women with dense breasts are needed due to their increased risk of breast cancer and of failed early diagnosis by screening mammography.
APA, Harvard, Vancouver, ISO, and other styles
7

Lozano, Adolfo, Jody C. Hayes, Lindsay M. Compton, and Fatemeh Hassanipour. "Pilot Clinical Study Investigating the Thermal Physiology of Breast Cancer via High-Resolution Infrared Imaging." Bioengineering 8, no. 7 (June 22, 2021): 86. http://dx.doi.org/10.3390/bioengineering8070086.

Full text
Abstract:
This descriptive study investigates breast thermal characteristics in females histologically diagnosed with unilateral breast cancer and in their contralateral normal breasts. The multi-institutional clinical pilot study was reviewed and approved by the Institutional Review Boards (IRBs) at participating institutions. Eleven female subjects with radiologic breast abnormalities were enrolled in the study between June 2019 and September 2019 after informed consent was obtained. Static infrared images were recorded for each subject. The Wilcoxon signed rank test was used to conduct paired comparisons in temperature data between breasts among the eight histologically diagnosed breast cancer subjects (n = 8). Localized temperatures of cancerous breast lesions were significantly warmer than corresponding regions in contralateral breasts (34.0 ± 0.9 °C vs. 33.2 ± 0.5 °C, p = 0.0142, 95% CI 0.25–1.5 °C). Generalized temperatures over cancerous breasts, in contrast, were not significantly warmer than corresponding regions in contralateral breasts (33.9 ± 0.8 °C vs. 33.4 ± 0.4 °C, p = 0.0625, 95% CI −0.05–1.45 °C). Among the breast cancers enrolled, breast cancers elevated temperatures locally at the site of the lesion (localized hyperthermia), but not over the entire breast (generalized hyperthermia).
APA, Harvard, Vancouver, ISO, and other styles
8

Leung, Jessica, Olena Weaver, Samir Hanash, and Jennifer Dennison. "Abstract P6-03-01: The MERIT Cohort: An MD Anderson Initiative to Integrate Blood and Imaging Biomarkers to Personalize Breast Cancer Risk." Cancer Research 83, no. 5_Supplement (March 1, 2023): P6–03–01—P6–03–01. http://dx.doi.org/10.1158/1538-7445.sabcs22-p6-03-01.

Full text
Abstract:
Abstract Background: The MERIT cohort (Mammography, Early Detection, Risk Assessment, and Imaging Technologies, 2017-present) has enrolled women receiving annual screening mammograms (MG) at MD Anderson with a primary goal to integrate clinical data and imaging data with blood biomarker profiles to determine risk of developing breast and other cancers. Here we report interim results for breast cancers among post-menopausal women in the cohort categorized based on breast density and BMI and differences between participants who underwent MRI/MG screening vs standard annual MG screening. Methods: The study annually collects comprehensive health measurements, questionnaire information, imaging data, and blood specimens. Plasma is processed and frozen within 4 hours of collection (draw-to-freezer, >500,000 aliquots to date) for biomarker research. Part of the cohort also has MRI screening every 6 months alternating with standard mammography (MRI/MG). BI-RADS breast density was determined by radiologist scoring using the baseline mammogram. Self-reported post-menopausal status (12 months without a menstrual period) was used to classify participants. When not available, those participants older than 50 years were classified as post-menopausal. Results: 4,392 of the 6,222 eligible subjects from MERIT were post-menopausal and included in the analyses. The average follow up was 2.4 mammograms per participant. MRI/MG screening was used for 385 (8.8%) participants who were more likely to be younger (59.6 vs 62.1 years, P< 0.01), have lower BMI (27.9 vs 28.6, P = 0.02) and dense breasts (64% vs 50%, P< 0.01). The rates of breast cancer were overall higher for those screened by MRI/MG vs standard MG (13.9 vs 6.9 cases per 1,000 mammograms). A total of 79 breast cancers (7.6 cases per 1,000 mammograms) were diagnosed with the highest rate of breast cancers in high BMI participants with dense breasts (see table). A blood-based biomarker profile for risk of breast cancer with high BMI was developed using matched pre-diagnostic plasma by mass spectrometry metabolomic analyses. Conclusions: The MERIT cohort has a higher-than-average rate of breast cancers, in part explained by a high-risk MRI/MG screening group. High BMI and dense breasts were generally associated with higher rates of breast cancer. The differences in the rates of breast cancer incidence for the high BMI group between non dense and dense breasts is likely understated for the standard mammogram group because of the lower sensitivity of mammography in dense breasts. Interestingly, the rates of breast cancers in the low BMI/non dense breast group were almost equally high as the low BMI/dense breast group, likely a result of reduced sensitivity of mammography for dense breasts. For future work, we will integrate the blood biomarker profiles with the breast density and BMI information to develop a more personalized risk model. MERIT Cohort Breast Cancers Rates of diagnosed breast cancers per 1,000 mammograms for post-menopausal women (N = 79 breast cancers)*‡P<0.01, †P<0.05, Fisher’s exact test Citation Format: Jessica Leung, Olena Weaver, Samir Hanash, Jennifer Dennison. The MERIT Cohort: An MD Anderson Initiative to Integrate Blood and Imaging Biomarkers to Personalize Breast Cancer Risk [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-03-01.
APA, Harvard, Vancouver, ISO, and other styles
9

Kaur, Mandeep. "Calcification Detection in Breast Cancer." International Journal of Psychosocial Rehabilitation 24, no. 4 (April 30, 2020): 5723–32. http://dx.doi.org/10.37200/ijpr/v24i4/pr2020377.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

B.D, Manjunath, Abhishek G., and Prem Kumar A. "Coagulation Abnormalities in Breast Cancer." New Indian Journal of Surgery 9, no. 2 (2018): 218–23. http://dx.doi.org/10.21088/nijs.0976.4747.9218.20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Breast – Cancer"

1

Vehmanen, Paula. "Breast cancer-predisposing genes in Finnish breast and ovarian cancer families." Helsinki : University of Helsinki, 2001. http://ethesis.helsinki.fi/julkaisut/mat/bioti/vk/vehmanen/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Alakhras, Maram Mustafa. "Breast tomosynthesis: Novel detection of breast cancer." Thesis, The University of Sydney, 2016. http://hdl.handle.net/2123/14222.

Full text
Abstract:
Purpose: To evaluate the impact of adding digital breast tomosynthesis (DBT) to digital mammography (DM) on radiologists’ performance, confidence and identification of lesions. Also, to evaluate the radiation dose from DBT and DM and to assess image quality at different dose levels. Methods: Twenty six radiologists examined 50 cases in two modes, DM and DM+DBT. The radiologists were classified into three groups as having no DBT experience, workshop DBT and clinical DBT. Radiologists were asked to localize breast lesions, report their type and give a score of 1-5. The first study examined radiologists’ performance by: sensitivity, location sensitivity, specificity, ROC AUC and JAFROC FOM. The second study, using the same case set, looked at the radiologists’ confidence and their ability to identify lesion type. The third study was a phantom-based experiment to evaluate the mean glandular dose using DBT and DM. Eleven readers reported the visibility of lesions for all phantom images on both modalities. Results: All performance measures were significantly higher for DM+DBT compared with DM AUCs (0.788 vs 0.681, p< 0.0001) and JAFROC (0.745 vs 0.621, p< 0.0001). Similar results were obtained for readers with no DBT and with clinical DBT experience. The confidence of radiologists using DM+DBT was significantly higher than DM in scoring cancer (p<0.0001) and normal cases (p= 0.018). The number of stellate lesions correctly reported on DM+DBT was significantly higher than with DM (p< 0.0001). The radiation dose at a thickness of 50 mm was 13% higher for DBT than for DM. The visibility of lesions was acceptable at 50% mAs for DBT and for DM. Conclusions: Addition of DBT to DM significantly improved: radiologists’ performance whether or not they have DBT experience; radiologists’ confidence and the number of stellate lesions compared with DM. DBT radiation dose is slightly higher than DM dose. However, the exposure may be reduced by 50% mAs with no change in image quality.
APA, Harvard, Vancouver, ISO, and other styles
3

Clark, Jacqueline. "Living with Breast Cancer: Emotion-Work Strategies in Breast Cancer Support Groups." NCSU, 2007. http://www.lib.ncsu.edu/theses/available/etd-03122007-104945/.

Full text
Abstract:
Research on stress and coping has attempted to explain how people deal with difficult life events, such as the diagnosis of a potentially life-threatening disease. Little attention, however, has been given to how people work together to cope with and manage the emotions evoked by such events. The present study looks at women who joined four breast cancer support groups to help them cope with the emotional fallout of the disease. Data from participant observation in these four groups, in addition to 35 in-depth interviews, are used to develop an analysis of how the women learned to cope collectively with their disease. Seven emotion-work strategies are identified and discussed, including: (a) seeking information; (b) concealing illness; (c) engaging in sexualized joking; (d) practicing compensatory femininity; (e) creating and sharing medicalized stories; (f) taking on the identity of breast cancer survivor; and (g) redefining illness as a blessing. The analysis shows how these strategies were influenced by the class-based resources the women brought with them to the groups. It also illustrates how these strategies (and thus the women?s coping efforts) were influenced and constrained by the mainstream breast cancer culture.
APA, Harvard, Vancouver, ISO, and other styles
4

Villman, Kenneth. "Chemosensitivity in Breast Cancer." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : [Univ.-bibl. [distributör]], 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-7459.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Haen, Roel. "Breast cancer related lymphedema." Thesis, University of Oxford, 2012. http://ora.ox.ac.uk/objects/uuid:c4a83ffc-790f-46ec-bde2-3ac639dd7c89.

Full text
Abstract:
Improvements in the treatment of breast cancer have resulted in better survival rates and less breast cancer related morbidity. Nevertheless, a significant group of patients still experience a diminished quality of life as a result of lymphedema. In the early, often reversible, stage of lymphedema patients can experience subjective changes in the affected area. However, with the traditionally available tools the lymphedema often remains clinically undetectable and patients are denied essential care that can prevent worsening. Furthermore, most lymphedema assessment tools fail to support a clear unambiguous definition of lymphedema. This underlines the need for a sensitive objective measurement method that can assess lymphedema in a subclinical stage. In this study we demonstrated that measuring tissue dielectric constant (TDC) using the MoistureMeter-D is an effective method to detect tissue water changes and could potentially provide a cost-effective adequate tool to measure the early onset of breast cancer related lymphedema (BCRL). Secondarily, we established the correlation between the novel TDC method and the frequently used arm volume measurements and self-assessment questionnaires. A group of 20 female patients with clinically BCRL were included. TDC measurements in both arms and all quadrant of both breast were recorded along with volumetric measurements of both arms. All patients were asked to complete a self-report questionnaire. The novel TDC method detected significantly higher tissue water levels in the affected arm and breast compared to the control side. The TDC ratio between control and affected side showed significant correlation with self-reported pain and discomfort in both arm and breast. In the arm, the TDC method also showed correlation with the volume measurement method. The TDC value of the arm was correlated to age, but not to BMI. This study demonstrates that measuring TDC using the MMD is an effective method for quantifying lymphedema in arm and breast and is an important tool in detecting early TWC changes.
APA, Harvard, Vancouver, ISO, and other styles
6

Bakir, Ayse. "Aluminium and breast cancer." Thesis, University of Reading, 2017. http://centaur.reading.ac.uk/72586/.

Full text
Abstract:
Al-based antiperspirant salts have been implicated as a causative factor in the development of breast cancer due to their proximity of application to the upper outer quadrant of the breast where the majority of breast cancers originate. Since mortality results from metastasis of breast cancer, this thesis has investigated the effects of Al chloride and Al chlorohydrate at 10-4M and 10-5M concentrations on the migratory and invasive abilities of four human breast cell lines. 10-5M was chosen as the concentration of Al previously measured in human nipple aspirate fluids. Effects on migration and invasion of MCF-7, MDA-MB-231, MCF-12A and HMF-3A human breast cells were explored using time-lapse microscopy, wound-healing assays and xCELLigence technology. Molecular pathways involving MMP-9, MMP-2, MMP-14, TIMP-1, TIMP-2, TIMP-3, ferritin and NDRG-1 were studied using RT-PCR, western immunoblotting and gelatin zymography. Prior exposure to Al increased the motility of MCF-7 cells after 32 weeks, of MDA-MB-231 cells after 25 weeks of prior exposure and of MCF-12A cells after 11 weeks. At a molecular level, Al chloride and Al chlorohydrate at 10 -5 M and 10 -4 M concentrations affected MMP-9 and MMP-14 mRNA and protein levels in MCF-7, MDA-MB-231 and MCF-12A cells. Although Al did not alter the motility of HMF-3A cells, changes in MMP-9, MMP-2 and MMP-14 mRNA expression and MMP-14 protein levels were found. Levels of the MMP inhibitors, TIMP 1, 2, and 3 were altered in MDA- MB-231 cells. Changes were observed in TIMP-3 levels in MCF-12A cells and TIMP-2 expression in HMF-3A cells. In considering the effects of Al on iron homeostasis, Al chloride was found to enhance ferritin levels in MCF-7 cells after 27weeks and in MCF-12A cells after 1week. Al chlorohydrate increased ferritin levels in MDAMB-231 cells after 21weeks. NDRG-1 mRNA and protein levels in MCF-7, MDA-MB-231 and MCF-12A cells were also affected but only NDRG-1 mRNA was altered in HMF-3A cells. Overall, it can be concluded that Al salts increase migration and invasion of human breast epithelial cells irrespective of whether they are transformed (MCF-7, MDA-MB-231cells) or not (MCF-12A cells), and irrespective of whether the cancer cells are oestrogen responsive (MCF-7 cells) or not (MDA-MB-231 cells). The changes observed in the levels of MMP-2, MMP-9 and MMP-14 and their inhibitors are indicative of a potential molecular pathway. The results demonstrate that exposure to Al chloride can increase ferritin levels, implicating alteration to iron homeostasis which is a known factor in the development of breast cancer. The results also showed that NDRG-1 expression, whose increase may depend on cell stress as for nickel, may not cause alterations observed in migration and invasion. In the light of these findings, it can be concluded that Al has mechanistic potential to cause metastatic tumour spread, which is the major reason for breast cancer mortality.
APA, Harvard, Vancouver, ISO, and other styles
7

Zeidan, Bashar. "Breast cancer biomarker discovery." Thesis, University of Southampton, 2013. https://eprints.soton.ac.uk/360029/.

Full text
Abstract:
Several environmental and genetic factors are involved in breast cancer development and prognosis. It is clear that mortality rate of breast and other cancers increase with advanced clinical and pathological stage. Early detection thus holds the best cure and identification of prospective markers for breast cancer early detection, as well as understanding the mechanisms of its tumourigenesis and metastatic spread are prerequisites for more effective disease management. This report describes our investigations in breast cancer biomarkers discovery. Here, serum samples from healthy volunteers and patients with breast tumours were analysed and compared to reveal diagnostic and prognostic breast cancer biomarkers. Biobanks hold a large number of samples that could provide statistically powerful cohorts with a wealth of lengthy follow up data; useful for pre disease / treatment biomarker discovery. However, ambiguous handling standards and source variability have limited their analysis. Conducting a two centre study, we illustrated that archival serum samples can be reliably analysed with high reproducibility. This highlights the utility of such samples for validation of markers discovered in recent studies. In addition, these samples could select for "real world" biologically stable marker entities. This work suggested that this is a potentially useful proteomic arena; however the corner stone for any future archival discovery projects remains dependent on multi centre immunovalidation. Breast cancer biomarkers including ER/PR and HER2 status; have led to targeted patient stratification and therapy. A more complex molecular sub classification could explain the different outcome within the disease sub groups. However, clinically reliable early detection and markers remain missing . Here, we investigated differentially expressed serum markers between non metastatic breast cancer, benign breast disease and healthy volunteers. Three validated candidate biomarkers (ANX A3, Apo Cl and a 6.4kDa biomarker) differentiating the three groups. Such breast cancer markers can be used as adjuncts to mammography. Further validation of these markers is ongoing and will be followed by elucidation of potential related molecular pathways. Finally, using a novel proteomic profiling platform, we identified and validated three prediction markers of post treatment outcome in early onset breast cancer. Here, ANX A2, Apo Cl and NOS2 were confirmed as serum prognosticators, and further validation and elucidation of their biological role in the disease holds promise for improved and personalised treatment regimes.
APA, Harvard, Vancouver, ISO, and other styles
8

Irwin, Gareth William. "BRCAness in breast cancer." Thesis, Queen's University Belfast, 2016. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.706986.

Full text
Abstract:
Background - Breast cancer can be defined various techniques such as immunohistochemistry, gene expression profiles and the presence of genetic mutations. One of these subgroups possesses a sensitivity to DNA-damaging chemotherapy, the BRCAness phenotype. It remains difficult to define this subgroup prior to treatment. This project aims to define BRCAness in breast cancer by assessing BRCAness using three methods: microarray profiling, immunohistochemistry and genetic mutations. Results - A 44 gene signature to predict DNA Damage Repair Deficient Breast cancers was developed from a training cohort of FFPE derived breast tumours enriched for BRCA1/2 mutant cancers. This signature was retrospectively applied to a cohort of sporadic breast cancers and subsequently validated as predictive for improved outcome in a cohort of early-stage breast cancers treated with anthracycline-based chemotherapy, a group that exhibits BRCAness. BRCA1 expression was measured by immunohistochemistry, however, this approach failed to predict benefit from chemotherapy in this study. Finally, a mutation, identified in SF3B1, plays a significant role in the DNA damage response and that absence or mutation of SF3B1 leads to sensitivity to DNA damage and this may be a predictor of BRCAness. Conclusion - In summary, we have shown that BRCAness is best defined by gene array profiling. We have shown that BRCA1 immunohistochemistry is of limited use for predicting patient outcomes in breast cancer. Finally, we identified of specific mutations within SF3B1 that induce sensitivity to DNA damage based chemotherapy.
APA, Harvard, Vancouver, ISO, and other styles
9

Jiao, Xiang. "Somatic Mutations in Breast Cancer Genomes : Discovery and Validation of Breast Cancer Genes." Doctoral thesis, Uppsala universitet, Institutionen för immunologi, genetik och patologi, 2012. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-182319.

Full text
Abstract:
Breast cancer is the most common cancer in women worldwide. However, the genetic alterations that lead to breast cancer are not fully understood. This thesis aims to identify novel genes of potential mechanistic, diagnostic or therapeutic interest in breast cancers by mutational analysis and whole-genome sequencing. In paper I, sequencing of 36 previously identified candidate genes in 96 breast tumors with patient-matched normal DNA determined the somatic mutation prevalence of these candidate genes and identified additional mutations in Notch, NF-κB, PI3K, and Hedgehog pathways as well as in processes mediating DNA methylation, RNA processing and calcium signaling. In paper II, comparison of massively parallel mate-pair sequencing results of a human genome before and after phi29-mediated multiple displacement amplification (MDA) revealed that MDA introduces structural alteration artifacts, with an emphasis on false positive inversions, and impairs the sensitivity to detect true inversions. Therefore, MDA has limited value in sample preparation for whole-genome sequencing for structural alteration detection. In paper III, massively parallel paired-end sequencing identified gene rearrangements in 15 hormone receptor negative breast cancers. Forty validated rearrangements were predicted to directly affect 30 genes, involved in epigenetic regulation, cell mitosis, signalling transduction and glycolytic flux. RNA interference-based assays revealed the potential roles in cell growth of some affected genes, among which DDX10 was implicated to be involved in apoptosis. In paper IV, a method for statistical evaluation of putative translocations detected by massively parallel paired-end sequencing was proposed. In an application of this method to analyse translocations detected by cancer genome deep paired-end sequencing, 76 putative translocations were classified into four categories, with the majority likely to be caused by mismapping due to repetitive regions. Taken together, this thesis provides insights into genes and pathways mutated in sporadic breast cancer genomes, which broaden our understanding of the genetic basis of breast cancer and may ultimately facilitate the diagnosis and treatment of this disease.
APA, Harvard, Vancouver, ISO, and other styles
10

Chen, Hsiu-Hsi. "Mathematical models for progression of breast cancer and evaluation of breast cancer screening." Thesis, University of Cambridge, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.388263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Breast – Cancer"

1

Bowcock, Anne M. Breast Cancer. New Jersey: Humana Press, 1999. http://dx.doi.org/10.1385/0896035603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Torosian, Michael H. Breast Cancer. New Jersey: Humana Press, 2002. http://dx.doi.org/10.1385/1592591612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Breast cancer. New York: Demos Medical, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Society, Oncology Nursing, ed. Breast cancer. 2nd ed. Pittsburgh, Pa: Oncology Nursing Society, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Sharma, Suresh Chander, Alok Mazumdar, and Robin Kaushik, eds. Breast Cancer. Singapore: Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-4546-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aydiner, Adnan, Abdullah Igci, and Atilla Soran, eds. Breast Cancer. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-96947-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Veronesi, Umberto, Aron Goldhirsch, Paolo Veronesi, Oreste Davide Gentilini, and Maria Cristina Leonardi, eds. Breast Cancer. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48848-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Francescatti, Darius S., and Melvin J. Silverstein, eds. Breast Cancer. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-8063-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Michell, Michael J., ed. Breast Cancer. Cambridge: Cambridge University Press, 2009. http://dx.doi.org/10.1017/cbo9780511676314.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Meden, Harald. Breast Cancer. Berlin, New York: Walter de Gruyter, 2009. http://dx.doi.org/10.1515/9783110212006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Breast – Cancer"

1

Antoine, E. Ch, O. Rixe, P. Pouillart, N. Renody, J. V. Chantelard, T. Petit, M. Weil, et al. "Breast cancer." In CT and MRI in Oncology, 133–42. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-46842-1_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bryce, Yolanda C. D., and Amy R. Deipolyi. "Breast Cancer." In Image-Guided Interventions in Oncology, 225–42. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-48767-6_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Karasawa, Kumiko. "Breast Cancer." In Carbon-Ion Radiotherapy, 303–7. Tokyo: Springer Japan, 2013. http://dx.doi.org/10.1007/978-4-431-54457-9_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fan, Fang. "Breast Cancer." In Breast Cancer and its Precursor Lesions, 41–51. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-154-7_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Turner, Bradley M., and David G. Hicks. "Breast Cancer." In Family Medicine, 1425–34. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-04414-9_114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kilbreath, Sharon L., and Elizabeth S. Dylke. "Breast Cancer." In Lymphedema, 879–85. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-52423-8_69.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Biganzoli, Laura, Catherine Oakman, Riccardo A. Audisio, and Ian Kunkler. "Breast Cancer." In Cancer and Aging Handbook, 241–67. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2013. http://dx.doi.org/10.1002/9781118312513.ch18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Davidson, Ben, and Fernando Schmitt. "Breast Cancer." In Serous Effusions, 239–58. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-76478-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kilbreath, Sharon L. "Breast Cancer." In Lymphedema, 501–5. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-567-5_60.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Davidson, Ben, and Fernando Schmitt. "Breast Cancer." In Serous Effusions, 205–23. London: Springer London, 2011. http://dx.doi.org/10.1007/978-0-85729-697-9_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast – Cancer"

1

Rodrigues, Milena de Freitas, Ariane Silva da Rocha, David Siqueira Gonçalves, Maria Paula Curado, and Maria Nirvana da Cruz Formiga. "Hereditary cancer syndromes in patients with second primary breast cancer." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1067.

Full text
Abstract:
Objective: The objective of this study was to evaluate the presence of hereditary cancer syndromes (HCS) in patients with a diagnosis of two primary breast carcinomas and analyze the frequency of pathogenic variants in high- and moderatepenetrance genes. Methodology: This is a retrospective unicentric cohort study on patients with a diagnosis of two primary breast cancers, diagnosed between January 2000 to December 2020, at A.C. Camargo Cancer Center, Brazil. The association between categorical variables was analyzed by the chi-square test or Fisher’s exact test. For survival curves, the Kaplan-Meier method and log-rank test were used to describe the survival curve differences. Results: Medical records of breast cancer patients were reviewed from 2000 to 2020, and a frequency of 600 patients with two primary breast tumors (metachronous or synchronous) was observed. In total, 190 (31.7%) patients performed genetic testing and 35 (5.8%) patients presented a pathogenic or likely-pathogenic germline variant in cancer predisposing genes. Conclusion: Our results revealed a low rate of genetic testing among patients with two primary breast cancers in a cancer center and a frequency of carrier patients lower than expected.
APA, Harvard, Vancouver, ISO, and other styles
2

Melo, Maria Eduarda Bernardino Martins, Gabriela Prado Lopes, Darley Lima Ferreira Filho, Irnanda Layanna Gomes Oliveira, and Maria Eduarda Vasconcelos Florêncio Cavalcanti. "MALE BILATERAL BREAST CANCER: CASE REPORT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1077.

Full text
Abstract:
Introduction: Breast cancer occurring bilaterally in men is extremely rare. Breast cancer represents 1% of all cancers, while bilateral cancer represents 5% of a total number of patients with breast cancer, which may be synchronic or metachronic. Many cases of breast cancer in men are detected between 60 and 70 years, with an average of 67 years of age. In men there is a tendency for late diagnosis at a more advanced stage than in women. Case report: A male patient, JSS, 68 years old, from Afogados da Ingazeira, state of Pernambuco, was seen with breast tumoration in June 2016. He arrived at the service with an existing diagnosis of breast cancer through core-biopsy examination. The physical exam presented bulging in the left retroareolar region and a hardened tumoration in palpation. Radical mastectomy was performed. The histopathological results confirmed an invasive mucinous carcinoma with histological grade I, nuclear grade II and mitotic grade I. Free margins. The most frequent histological type in men is ductal (85%–90%), followed by papillary in 4.5% and mucinous in 2.8% of the cases. Nineteen free axillary lymph nodes were dissected, with Estrogen and Progesterone + receptors, Her-2, negative and with Ki-67 of 5%. Breast cancers in men present with more positivity for hormone receptors and low expression for Her-2. The pathological staging was classified as II a. The patient was being followed by the clinical oncology department, where he was chosen not to do chemotherapy and only hormone therapy, with Tamoxifen 20 mg. However, over a period of six months he noticed the presence of a tumoration in the right breast. An image examination was performed with MG/USG, which confirmed the presence of a tumor in the right retro-areolar region (Birads IV). A core-biopsy of the lesion was requested, which confirmed an invasive breast cancer. The patient underwent right radical mastectomy, whose result confirmed an invasive ductal carcinoma with pathological staging II a. Conclusion: This pathology is extremely rare in men and the evaluation of the contralateral breast is of fundamental importance. Early diagnosis and compliance with treatment will reduce tumor recurrence and provide a better prognosis for these patients.
APA, Harvard, Vancouver, ISO, and other styles
3

El-Helou, Etienne, Catalin-Florin Pop, Ammar Shall, Manar Zaiter, Jessica Naccour, Huu Hoang, Thi Hoa Nguyen, and Xuan Dung Ho. "PRIMARY INVASIVE DUCTAL CARCINOMA OF AXILLARY ACCESSORY BREAST." In Brazilian Breast Cancer Symposium 2022. Mastology, 2022. http://dx.doi.org/10.29289/259453942022v32s2094.

Full text
Abstract:
Primary accessory breast cancer is an extremely rare pathology, representing less than 1% of all breast cancers, and it is found in more than 90% of cases in the axilla. The diagnosis of accessory axillary breast cancer (AABC) is often late and at an advanced stage, with an average delay of 40.5 months. Histological sampling and immunohistochemical results confirm the diagnosis. Most patients are diagnosed with stage II disease or higher, so it is considered to have a poor prognosis. There is no proper management for AABC; it follows the guidelines for orthotopic pectoral breast cancer. We therefore report the case of a 50-year-old woman diagnosed with grade II invasive ductal carcinoma found in accessory axillary breast, treated with neoadjuvant chemotherapy followed by a wide local resection and axillary lymph node dissection.
APA, Harvard, Vancouver, ISO, and other styles
4

Batista, Maria Stefania Nóbrega, and Lara Moreira Mendes Carneiro. "Association between obesity and breast cancer in premenopause." In II INTERNATIONAL SEVEN MULTIDISCIPLINARY CONGRESS. Seven Congress, 2023. http://dx.doi.org/10.56238/homeinternationalanais-025.

Full text
Abstract:
Abstract In Brazil, excluding non-melanoma skin tumors, breast cancer is the most common in women. The number of cancer deaths also increased, from 6.2 million in 2000 to 10 million in 2020. More than one in six deaths is due to cancer (WHO, 2021). In addition to well-established risk factors such as female gender, age, positive family history, genetic mutations, proliferative breast changes, high breast density breasts, early menarche, late menopause and radiation exposure, some researchers associate body constitution with the risk of breast cancer development. As obesity and cancer are diseases that affect millions of people and have important consequences it is necessary to identify the relationship between these two events.
APA, Harvard, Vancouver, ISO, and other styles
5

"Case series: Breast and ovarian cancer syndrome." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685364.

Full text
Abstract:
Aims and Objectives: To report a series of cases with breast and ovarian carcinomas either in same patient or in a family and identifying the importance of BRCA 1, 2 genetic testing in such individuals. Materials and Methods: The medical records of breast and ovarian cancer patients operated over past 3 years at a single institute were reviewed retrospectively and their clinical profile, family history, final pathological reports and follow up data was collected. Results: 8 patients were found to have breast and ovarian malignancies, out of which 3 had synchronous breast and ovarian cancers, 4 had metachronous and 1 patient with ovarian cancer had history of breast cancer in family. Median age of presentation to the hospital was 47 years and median time interval in metachronous disease patients was 5.5 years. Conclusion: About 5% of people who have breast cancer and about 10% of women who have ovarian cancer have HBOC, caused by germline mutation in BRCA 1, 2 gene. These individuals have increased risk of developing breast cancer at younger age, TNBC, or developing a second primary in breast or ovary plus an overall risk of breast/ovarian/prostate/pancreatic malignancies in other family members due to inheritable mutation. Identification of BRCA mutation in such individuals can help family members to undergo genetic counseling and follow different screening and prevention guidelines from general population thus reducing the cancer risks.
APA, Harvard, Vancouver, ISO, and other styles
6

"Case series: Breast and ovarian cancer syndrome." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685348.

Full text
Abstract:
Aims and Objectives: To report a series of cases with breast and ovarian carcinomas either in same patient or in a family and identifying the importance of BRCA 1,2 genetic testing in such individuals. Materials and Methods: The medical records of breast and ovarian cancer patients operated over past 3 years at a single institute were reviewed retrospectively and their clinical profile, family history, final pathological reports and follow up data was collected. Results: 8 patients were found to have breast and ovarian malignancies, out of which 3 had synchronous breast and ovarian cancers, 4 had metachronous and 1 patient with ovarian cancer had history of breast cancer in family. Median age of presentation to the hospital was 47 years and median time interval in metachronous disease patients was 5.5 years. Conclusion: About 5% of people who have breast cancer and about 10% of women who have ovarian cancer have HBOC, caused by germline mutation in BRCA1, 2 gene. These individuals have increased risk of developing breast cancer at younger age, TNBC, or developing a second primary in breast or ovary plus an overall risk of breast/ovarian/prostate/pancreatic malignancies in other family members due to inheritable mutation. Identification of BRCA mutation in such individuals can help family members to undergo genetic counseling and follow different screening and prevention guidelines from general population thus reducing the cancer risks.
APA, Harvard, Vancouver, ISO, and other styles
7

Moreno, Andre, Kimberly Masiero Cola, Larissa Heberle, and Marcelo Moreno. "RELATIONSHIP BETWEEN IMMUNOHISTOCHEMICAL CHARACTERIZATION AND FORM OF DIAGNOSIS OF BREAST CANCER." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1008.

Full text
Abstract:
Introduction: Breast cancer is the most incident neoplasia among Brazilian women. According to immunogenetic characteristics, it is possible to verify that malignant breast neoplasms with greater biological activity would be those classified as luminary B, HER2+ and triple-negative, and that the one with the lowest biological activity would be the luminal subtype A. Thus, a mammography would be more likely to detect cancers with a low degree of biological characteristics such as “luminal A”. On the other hand, mammary carcinomas with greater potential for systemic dissemination show faster growth in the breast parenchyma and are detected predominantly by self-examination. Knowledge of this difference in the clinical behavior of mammary malignant neoplasms is important for the diagnosis of “interval” breast cancers, that is, breast cancer that appears in the period between the performance of annual screening mammograms. Objectives: Verify the relationship between immunohistochemical characterization of malignant breast neoplasms and the finding that motivated the medical consultation, in women with breast cancer and residents of Western Santa Catarina, Brazil. Methods: Observational, cross-sectional study, which included women diagnosed with breast cancer and treated at an oncology referral center in the city of Chapecó, state of Santa Catarina, Brazil, from January 2000 to December 2016. Patients that presented medical records whose main complaint was towards the diagnosis of breast cancer were included (example: nodule diagnosed by imaging exams, self-examination, clinical examination). Besides this, the breast injury related to this complaint should have been breast cancer diagnosed by an anatomopathological examination and an immunohistochemistry study. The project was developed in accordance to CEP/UNOCHAPECO no. 1819869. Results: Data from 209 patients were analyzed, from which 83 (39.7%) cases of breast cancer were detected by a mammography examination; 115 (55%) cases by breast self-examination and 11 (5.2%) cases by other forms of examination, which included clinical breast examination done by a doctor, magnetic resonance imaging and ultrasound. The luminal A immunohistochemical profile was more prevalent among patients who underwent breast cancer detection through mammography (62.6%). There was a correlation between lymph node invasion and the screening method, in which 78.6% of cancers detected by self-examination showed expansion to lymph nodes, while those detected by mammography presented an invasion rate of 45.7% (p=0.002). Conclusions: Breast cancer with immunohistochemical characterization, related to greater biological activity, were most often detected by self-examination, while neoplasms with indolent development were diagnosed predominantly by mammography.
APA, Harvard, Vancouver, ISO, and other styles
8

Reis, Yedda Nunes, Bruna Salani Mota, Marcos Desiderio Ricci, Carlos Shimizu, Fernando Nalesso Aguiar, Natalia Paula Cardoso, Edmund Chada Baracat, and José Roberto Filassi. "MACROSCOPIC EXAMINATION OF BREAST DENSITY CORRELATION WITH MAMMOGRAPHIC BREAST DENSITY IN BREAST CANCER–CONSERVING SURGERY: A RETROSPECTIVE ANALYSIS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2059.

Full text
Abstract:
Objective: The aim of this study is to evaluate the association between mammographic breast density (MBD) and macroscopic examination of breast density (MEBD), as well as the association between MEBD and multiple clinical and tumoral characteristics. Methodology: The secondary (i.e., retrospective) analysis from a prospective database (BREAST-MRI trial) was performed. Patients with breast cancer stages 0 to III for breast-conserving surgery, from November 2014 to October 2018, were selected. All patients were evaluated with clinical examination, breast ultrasound, and mammography and stratified by MBD. Then, they were randomized on a 1:1 basis in two groups whether to perform breast magnetic resonance imaging. Analysis of the subset of patients’ MEBD in the clinical trial was not prespecified. MEBD was estimated by calculating the ratio of stromal and fatty tissues in each breast histopathological sample, and then, patients were classified similarly to ACR BI-RADS® criteria. Results: A total of 431 MEBD were selected for the analysis. MEBD classification was distributed as follows: 303 (70.3%) were classified as A, 85 (19.7%) as B, 36 (8.4%) as C, and 7 (1.6%) as D. There is no association between MBD and MEBD in our breast surgical specimens, such that MEBD A, B, C, and D were associated with MBD in 22 (97.1%) of 24 A breasts, 34 (18.2%) of 187 B breasts, 26 (13.1%) of 199 C breasts, and 1 (4.8%) of 21 D breasts (p<0.001). Breasts with the highest fat content in the macroscopic analysis were associated with older patients, higher body mass index, multiparity, and postmenopausal status (p=0.001). There was no difference among groups regarding the history of hormone replacement therapy, clinical stage, and immunohistochemical. Conclusion: Our study shows that MEBD does not hold a close correlation with MBD, according to the ACR BI-RADS classification.
APA, Harvard, Vancouver, ISO, and other styles
9

Rocha, Ariane Silva da, Gisele Aparecida Fernandes, Cynthia Aparecida Bueno de Toledo Osório, Ruffo de Freitas-Júnior, and Maria Paula Curado. "Overall survival in patients with second primary breast cancer." In Brazilian Breast Cancer Symposium 2023. Mastology, 2023. http://dx.doi.org/10.29289/259453942023v33s1061.

Full text
Abstract:
Objective: The objective of this study was to analyze the overall survival of patients with second primary synchronous and metachronous breast cancer. Methodology: A retrospective cohort study on women with second primary breast cancer, diagnosed between 2000 and 2015, was conducted. The cases were drawn from the Cancer Hospital registry and classified according to the hospital registry rules for second primary cancers. The second primary breast tumor was defined as synchronous or metachronous according to the diagnosis of the second cancer: ≤6 months of the first tumor and >6 months after the first tumor, respectively (Newman et al. 2001). Survival curves were estimated using the Kaplan-Meier method. Results: A total of 11,922 women with breast cancer were identified between 2000 and 2015. Of these cases, 3.24% (375) had second primary breast cancer, comprising 60.8% (228) synchronous and 39.2% (147) metachronous tumors. Regarding age, patients were predominantly in the ≥60 years age accounting for 39.9% (91) of synchronous and 48.3% (71) of metachronous cases, with a mean patient age of 55 years for synchronous and 59 years for metachronous tumors. Overall, 5-year survival in women with synchronous breast cancer was 86.5% (95%CI 79.69–91.21) and with metachronous cancer was 82.1% (95%CI 73.71–88.10), while 10-year survival was 69% for both synchronous and metachronous. Conclusion: There was no difference in overall survival of patients with second primary synchronous and metachronous at 5 and 10 years after treatment. However, in this cohort, we were not able to investigate the genetics profile to identify the presence of associated genetic syndromes, a factor that can modify our findings.
APA, Harvard, Vancouver, ISO, and other styles
10

Queiroz, Andrei Alves de, Debora Garcia y. Narvaiza, Ana Maria Kemp, and Gisele Tolaini Gomes Pereira. "LOBULAR BREAST CARCINOMA: THE RISK FOR CONTRALATERAL BREAST IS NOT PERMANENT." In Scientifc papers of XXIII Brazilian Breast Congress - 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s1028.

Full text
Abstract:
Introduction: The invasive lobular carcinoma of the breast occurs in approximately 10% of breast cancers. The increased risk for multicentric and bilateral breast tumor is well-documented in the literature, but few data is available regarding the interval for occurrence of contralateral tumors. Objectives: This study aims to analyze the characteristics of the bilaterality of the lobular tumor and time to the occurrence of the bilateral tumor in comparison with non-lobular tumors. Methods: Retrospective, analytical study from the American Surveillance, Epidemiology and End Results Program (SEER) database. Patients with unilateral and bilateral breast cancer (synchronous and metachronous) were filtered from this database in women aged 20 to 75 years from 2000 to 2017. Patients with cancers diagnosed in other organs were excluded. Definitions: Lobular carcinoma at the first diagnosis (LC): patients with lobular breast cancer at the diagnosis of the first neoplasm. Non-lobular carcinoma (NLC): patients with non-lobular carcinoma (ductal or special type) at diagnosis of the first neoplasm. Results: We identified 560,608 patients with breast cancer, 19,792 of which were patients with bilateral tumors (3.5%) and 45,156 (8.0%) lobular tumors at the first diagnosis. Patients with LC had significantly more tumors in both breasts throughout the research period (6.3% vs. 3.3%; OR: 1.97; 95%CI 1.89–2.06, p <0.001). The time for occurrence of contralateral tumor varied widely between patients with lobular and non-lobular tumors. The LC patients presented the diagnosis of contralateral breast tumor much earlier, with 50% of the contralateral tumors diagnosed within one month, and 75% in the first three months, while the NLC patients presented 50% of the contralateral tumors in the first three months and 75% after 54 months of follow-up. Cox’s multivariate analysis shows a higher risk of contralateral breast involvement in LC patients when corrected by age and estrogen receptor expression (RR 2.0; 95%CI 1.93–2.09; p <0.001). This increased risk is not sustained when patients with a tumor in an interval greater than 12 months (RR 1.04; 95%CI 0.96–1.14; p=0.3). Conclusions: Invasive lobular carcinoma is associated with a higher incidence of contralateral disease, but the higher risk occurs in the first year of follow-up. After the one-year period, the incidence of contralateral breast cancer is similar in lobular and non-lobular cancers.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast – Cancer"

1

Shumway, Dean A., Kimberly S. Corbin, Magdoleen H. Farah, Kelly E. Viola, Tarek Nayfeh, Samer Saadi, Vishal Shah, et al. Partial Breast Irradiation for Breast Cancer. Agency for Healthcare Research and Quality (AHRQ), January 2023. http://dx.doi.org/10.23970/ahrqepccer259.

Full text
Abstract:
Objectives. To evaluate the comparative effectiveness and harms of partial breast irradiation (PBI) compared with whole breast irradiation (WBI) for early-stage breast cancer, and how differences in effectiveness and harms may be influenced by patient, tumor, and treatment factors, including treatment modality, target volume, dose, and fractionation. We also evaluated the relative financial toxicity of PBI versus WBI. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, Scopus, and various grey literature sources from database inception to June 30, 2022. Review methods. We included randomized clinical trials (RCTs) and observational studies that enrolled adult women with early-stage breast cancer who received one of six PBI modalities: multi-catheter interstitial brachytherapy, single-entry catheter brachytherapy (also known as intracavitary brachytherapy), 3-dimensional conformal external beam radiation therapy (3DCRT), intensity-modulated radiation therapy (IMRT), proton radiation therapy, intraoperative radiotherapy (IORT). Pairs of independent reviewers screened and appraised studies. Results. Twenty-three original studies with 17,510 patients evaluated the comparative effectiveness of PBI, including 14 RCTs, 6 comparative observational studies, and 3 single-arm observational studies. PBI was not significantly different from WBI in terms of ipsilateral breast recurrence (IBR), overall survival, or cancer-free survival at 5 and 10 years (high strength of evidence [SOE]). Evidence for cosmetic outcomes was insufficient. Results were generally consistent when PBI modalities were compared with WBI, whether compared individually or combined. These PBI approaches included 3DCRT, IMRT, and multi-catheter interstitial brachytherapy. Compared with WBI, 3DCRT showed no difference in IBR, overall survival, or cancer-free survival at 5 and 10 years (moderate to high SOE); IMRT showed no difference in IBR or overall survival at 5 and 10 years (low SOE); multi-catheter interstitial brachytherapy showed no difference in IBR, overall survival, or cancer-free survival at 5 years (low SOE). Compared with WBI, IORT was associated with a higher IBR rate at 5, 10, and over 10 years (high SOE), with no difference in overall survival, cancer-free survival, or mastectomy-free survival (low to high SOE). There were significantly fewer acute adverse events (AEs) with PBI compared with WBI, with no apparent difference in late AEs (moderate SOE). Data about quality of life were limited. Head-to-head comparisons between the different PBI modalities showed insufficient evidence to estimate an effect on main outcomes. There were no significant differences in IBR or other outcomes according to patient, tumor, and treatment characteristics; however, data for subgroups were insufficient to draw conclusions. Eight studies addressed concepts closely related to financial toxicity. Compared with conventionally fractionated WBI, accelerated PBI was associated with lower transportation costs and days away from work. PBI was also associated with less subjective financial difficulty at various time points after radiotherapy. Conclusions. Clinical trials that compared PBI with WBI demonstrate no significant difference in the risk of IBR. PBI is associated with fewer acute AEs and may be associated with less financial toxicity. The current evidence supports the use of PBI in appropriately selected patients with early-stage breast cancer. Further investigation is needed to evaluate the outcomes of PBI in patients with various clinical and tumor characteristics, and to define optimal radiation treatment dose and technique for PBI.
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, Ying yuan, Zechang Chen, Luxin Zhang, Shuangyi Chen, Zhuomiao Ye, Tingting Xu, and Yingying Zhang c. A systematic review and network meta-analysis: Role of SNPs in predicting breast carcinoma risk. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, February 2022. http://dx.doi.org/10.37766/inplasy2022.2.0092.

Full text
Abstract:
Review question / Objective: P: Breast cancer patient; I: Single nucleotide polymorphisms associated with breast cancer risk; C: Healthy person; O: By comparing the proportion of SNP mutations in the tumor group and the control group, the effect of BREAST cancer risk-related SNP was investigated; S: Case-control study. Condition being studied: Breast cancer (BC) is one of the most common cancers among women, and its morbidity and mortality have continued to increase worldwide in recent years, reflecting the strong invasiveness and metastasis characteristics of this cancer. BC is a complex disease that involves a sequence of genetic, epigenetic, and phenotypic changes. Polymorphisms of genes involved in multiple biological pathways have been identified as potential risks of BC. These genetic polymorphisms further lead to differences in disease susceptibility and severity among individuals. The development of accurate molecular diagnoses and biological indicators of prognosis are crucial for individualized and precise treatment of BC patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Corkum, Eleanor, Tiffanie Perrault, and Erin C. Strumpf. Improving Breast Cancer Diagnosis Pathways in Quebec. CIRANO, October 2023. http://dx.doi.org/10.54932/qsho2261.

Full text
Abstract:
Delays in breast cancer diagnosis can worsen the severity of illness and reinforce inequalities. This report analyzes Quebec’s capabilities and performance along the diagnosis pathway, gathering information from the scientific literature on cancer care, government reports, and expert interviews. The first section outlines which types of breast cancer data Quebec collects, and how data availability impacts the measurement of performance indicators. The second section discusses how socio-economic factors and unclear guidelines for patients outside Quebec’s organized screening program create barriers to diagnosis. We also explore how Quebec’s lack of standardized and integrated care and its outdated cancer registry can create further delays and inefficiencies. The final section of the report compares innovations in breast cancer diagnosis in Quebec to those in Alberta and Ontario, where diagnostic delays are shorter. This comparison suggests that Quebec should include high-risk individuals in its screening program, create personalized screening recommendations, update available imaging and genetic testing technologies, and modernize communication methods. Relevant research and initiatives seeking to increase screening adherence among groups with low screening rates are also discussed. Overall, this paper highlights tangible strategies to shorten and streamline the breast cancer diagnosis interval, and points the reader to key resources for further investigation.
APA, Harvard, Vancouver, ISO, and other styles
4

Tangka, Florence K. L., Sujha Subramanian, Madeleine Jones, Patrick Edwards, Sonja Hoover, Tim Flanigan, Jenya Kaganova, et al. Young Breast Cancer Survivors: Employment Experience and Financial Well-Being. RTI Press, July 2020. http://dx.doi.org/10.3768/rtipress.2020.rr.0041.2007.

Full text
Abstract:
The economic burden of breast cancer for women under 50 in the United States remains largely unexplored, in part because young women make up a small proportion of breast cancer cases overall. To address this knowledge gap, we conducted a web-based survey to compare data from breast cancer survivors 18–39 years of age at first diagnosis and 40–49 years of age at first diagnosis. We administered a survey to a national convenience sample of 416 women who were 18–49 years of age at the time of their breast cancer diagnosis. We analyzed factors associated with financial decline using multivariate regression. Survivors 18–39 years of age at first diagnosis were more likely to report Stage II–IV breast cancer (P<0.01). They also quit their jobs more often (14.6%) than older survivors (4.4%; P<0.01) and faced more job performance issues (55.7% and 42.8%, respectively; P=0.02). For respondents in both groups, financial decline was more likely if the survivor had at least one comorbid condition (odds ratios: 2.36–3.21) or was diagnosed at Stage II–IV breast cancer (odds ratios: 2.04–3.51).
APA, Harvard, Vancouver, ISO, and other styles
5

Qin, Zhuzhu, Xutong Zheng, Xiaoling Zou, Danfeng Chen, Simin Huang, Bichun Huang, and Chenju Zhan. Status Quo of Stigma and Correlated Psychological Factors Among Breast Cancer Patients in China: A Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2023. http://dx.doi.org/10.37766/inplasy2023.4.0012.

Full text
Abstract:
Review question / Objective: This meta-analysis aimed to evaluate the level of stigma and the associated psychological factors among Chinese breast cancer patients. Condition being studied: According to the latest global cancer burden statistics provided by the International Agency for Research on Cancer (IARC) of the World Health Organization in 2020, breast cancer accounts for approximately 30% of the most common malignancies diagnosed in women worldwide.Breast cancer is a significant health concern for women in China. The estimated population diagnosed with breast cancer has been rising, with the estimated 2.5 million cases over the next decade. Despite the positive impact of advanced surgical treatment options, breast cancer patients often face additional challenges, such as breast deficiency, scarring, limb dysfunction, and altered body image. These physical changes can lead to psychological issues, such as a strong sense of shame and avoidance of reality, among breast cancer survivors. Therefore, it is important for medical professionals to consider not only the physical aspects of breast cancer treatment but also the psychological well-being of patients.
APA, Harvard, Vancouver, ISO, and other styles
6

Thompson, Hayley. Increasing Breast Cancer Surveillance among African American Breast Cancer Survivors. Fort Belvoir, VA: Defense Technical Information Center, July 2005. http://dx.doi.org/10.21236/ada443782.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thompson, Hayley. Increasing Breast Cancer Surveillance Among African American Breast Cancer Survivors. Fort Belvoir, VA: Defense Technical Information Center, July 2004. http://dx.doi.org/10.21236/ada428939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Gonzalez-Perez, Ruben R. Targeting Breast Cancer Stem Cells In Triple Negative Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2014. http://dx.doi.org/10.21236/ada613188.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Thompson, Hayley. Increasing Breast Cancer Surveillance Among African American Breast Cancer Survivors. Fort Belvoir, VA: Defense Technical Information Center, January 2010. http://dx.doi.org/10.21236/ada535491.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Thompson, Hayley. Increasing Breast Cancer Surveillance Among African American Breast Cancer Survivors. Fort Belvoir, VA: Defense Technical Information Center, July 2009. http://dx.doi.org/10.21236/ada514018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Breast – Cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography